FDA OKs Immunicon's rare cell collection tube
This article was originally published in Clinica
Executive Summary
Cancer diagnostic firm Immunicon has received US FDA clearance to market a blood collection tube that preserves circulating tumour cells. The New York company believes its CellSave preservative tube to be the only one of its kind currently available. A spokesperson for the firm told Clinica: "To our knowledge there is no such 'draw tube' on the market today for preserving circulating tumour cells, which have potential medical utility in the management of cancer patients."
You may also be interested in...
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.
EU Stakeholders Devise Six-Point Plan To Improve Cross-Border Clinical Trials
Sponsors need guidance on ethics requirements and clarity around national regulations to conduct cross-border clinical trials in the EU, a multi-stakeholder forum says.